With the gradual aggravation of global aging problem, the prevalence of chronic diseases and mortality in elderly people are rapidly increasing, resulting in a massive disease burden. Managing chronic diseases is an important initiative to promote healthy aging. Sarcopenia and hypertension are both diseases associated with aging, and studies have shown that there is a significant relationship between them. In this paper, we will review the correlation studies on sarcopenia and hypertension in recent years, aiming to explore the possible links between them, and provide more effective strategies for prevention and treatment.

Xiaoxue Wu, Kun Zheng, Li Xia. Research Progress on the Correlation between Sarcopenia and Hypertension in Elderly People. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 5: 18-26. https://doi.org/10.25236/IJFM.2024.060504.

[1] Rosenberg, I.H., Epidemiologic and methodologic problems in determining nutritional-status of older persons – proceedings of a conference held in Albuquerque, New Mexico, October 19–21, 1988 – summary comments. The American Journal of Clinical Nutrition, 1989. 50(5):1231-1233.

[2] Anker, S.D., J.E. Morley, and S. von Haehling, Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle, 2016. 7(5):512-514.

[3] Studenski, S.A., K.W. Peters, D.E. Alley, et al., The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci, 2014. 69(5):547-558.

[4] Cruz-Jentoft, A.J., G. Bahat, J. Bauer, et al., Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 2019. 48(1):16-31.

[5] Chen, L.-K., J. Woo, P. Assantachai, et al., Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. Journal of the American Medical Directors Association, 2020. 21(3):300.

[6] Kingsley, J., K. Torimoto, T. Hashimoto, et al., Angiotensin II inhibition: a potential treatment to slow the progression of sarcopenia. Clin Sci (Lond), 2021. 135(21):2503-2520.

[7] Janssen, I., D.S. Shepard, P.T. Katzmarzyk, et al., The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc, 2004. 52(1):80-85.

[8] Curcio, F., G. Ferro, C. Basile, et al., Biomarkers in sarcopenia: A multifactorial approach. Exp Gerontol, 2016. 85:1-8.

[9] Cruz-Jentoft, A.J., J.P. Baeyens, J.M. Bauer, et al., Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing, 2010. 39(4):412-423.

[10] Chen, L.-K., L.-K. Liu, J. Woo, et al., Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia. Journal of the American Medical Directors Association, 2014. 15(2):95-101.

[11] Fielding, R.A., B. Vellas, W.J. Evans, et al., Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc, 2011. 12(4):249-256.

[12] Baumgartner, R.N., K.M. Koehler, D. Gallagher, et al., Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol, 1998. 147(8):755-763. 

[13] Petermann-Rocha, F., V. Balntzi, S.R. Gray, et al., Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. Journal of Cachexia Sarcopenia and Muscle, 2022. 13(1):86-99.

[14] Patel, H.P., H.E. Syddall, K. Jameson, et al., Prevalence of sarcopenia in community-dwelling older people in the UK using the European Working Group on Sarcopenia in Older People (EWGSOP) definition: findings from the Hertfordshire Cohort Study (HCS). Age Ageing, 2013. 42(3):378-384.

[15] Guillamón-Escudero, C., A. Diago-Galmés, J.M. Tenías-Burillo, et al., Prevalence of Sarcopenia in Community-Dwelling Older Adults in Valencia, Spain. Int J Environ Res Public Health, 2020. 17(23).

[16] Makizako, H., Y. Nakai, K. Tomioka, et al., Prevalence of sarcopenia defined using the Asia Working Group for Sarcopenia criteria in Japanese community-dwelling older adults: A systematic review and meta-analysis. Phys Ther Res, 2019. 22(2):53-57.

[17] Pang, B.W.J., S.L. Wee, L.K. Lau, et al., Prevalence and Associated Factors of Sarcopenia in Singaporean Adults-The Yishun Study. J Am Med Dir Assoc, 2021. 22(4):885.e881-885.e810.

[18] Hu, X., J. Jiang, H. Wang, et al., Association between sleep duration and sarcopenia among community-dwelling older adults: A cross-sectional study. Medicine (Baltimore), 2017. 96(10):e6268.

[19] Vasan, R.S., M.G. Larson, E.P. Leip, et al., Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med, 2001. 345(18):1291-1297.

[20] Zhao, D., J. Liu, M. Wang, et al., Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol, 2019. 16(4):203-212.

[21] Wang, Z., Z. Chen, L. Zhang, et al., Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015. Circulation, 2018. 137(22):2344-2356.

[22] Ata, A.M., M. Kara, T. Ekiz, et al., Reassessing Sarcopenia in Hypertension: STAR and ACE Inhibitors Excel. International Journal of Clinical Practice, 2021. 75(3).

[23] Kurose, S., S. Nishikawa, T. Nagaoka, et al., Prevalence and risk factors of sarcopenia in community-dwelling older adults visiting regional medical institutions from the Kadoma Sarcopenia Study. Scientific Reports, 2020. 10(1).

[24] Bai, T., F. Fang, F. Li, et al., Sarcopenia is associated with hypertension in older adults: a systematic review and meta-analysis. Bmc Geriatrics, 2020. 20(1).

[25] Buvinic, S., J. Balanta-Melo, K. Kupczik, et al., Muscle-Bone Crosstalk in the Masticatory System: From Biomechanical to Molecular Interactions. Front Endocrinol (Lausanne), 2020. 11:606947.

[26] Dumurgier, J., A. Elbaz, C. Dufouil, et al., Hypertension and lower walking speed in the elderly: the Three-City study. J Hypertens, 2010. 28(7):1506-1514.

[27] So, W.Y., Association between Grip Strength and Hypertension States in Elderly Korean Individuals. Iran J Public Health, 2020. 49(5):1001-1003.

[28] Dipla, K., A. Triantafyllou, N. Koletsos, et al., Impaired Muscle Oxygenation and Elevated Exercise Blood Pressure in Hypertensive Patients Links With Vascular Stiffness. Hypertension, 2017. 70(2):444.

[29] Zhao, Q., J.M. Zmuda, A.L. Kuipers, et al., Muscle Attenuation Is Associated With Newly Developed Hypertension in Men of African Ancestry. Hypertension, 2017. 69(5):957-963.

[30] Mitchell, W.K., J. Williams, P. Atherton, et al., Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol, 2012. 3:260.

[31] Wiedmer, P., T. Jung, J.P. Castro, et al., Sarcopenia - Molecular mechanisms and open questions. Ageing Research Reviews, 2021. 65.

[32] Li, C.-w., K. Yu, N. Shyh-Chang, et al., Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review. Journal of Cachexia Sarcopenia and Muscle, 2022. 13(2):781-794.

[33] Han, J.M., M.-Y. Lee, K.-B. Lee, et al., Low relative skeletal muscle mass predicts incident hypertension in Korean men: a prospective cohort study. Journal of Hypertension, 2020. 38(11):2223-2229.

[34] Rudman, D., A.G. Feller, H.S. Nagraj, et al., Effects of human growth hormone in men over 60 years old. N Engl J Med, 1990. 323(1):1-6.

[35] Siti, H.N., Y. Kamisah, and J. Kamsiah, The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascul Pharmacol, 2015. 71:40-56.

[36] Alemán, H., J. Esparza, F.A. Ramirez, et al., Longitudinal evidence on the association between interleukin-6 and C-reactive protein with the loss of total appendicular skeletal muscle in free-living older men and women. Age Ageing, 2011. 40(4):469-475.

[37] Quan, Y., C. Wang, L. Wang, et al., Geriatric sarcopenia is associated with hypertension: A systematic review and meta-analysis. J Clin Hypertens (Greenwich), 2023. 25(9):808-816.

[38] Can, B., O. Kara, M.C. Kizilarslanoglu, et al., Serum markers of inflammation and oxidative stress in sarcopenia. Aging Clin Exp Res, 2017. 29(4):745-752.

[39] Liguori, I., G. Russo, F. Curcio, et al., Oxidative stress, aging, and diseases. Clinical Interventions in Aging, 2018. 13:757-772.

[40] Cheek, D.B., The control of cell mass and replication. The DNA unit--a personal 20-year study. Early Hum Dev, 1985. 12(3):211-239.

[41] Marzetti, E., R. Calvani, M. Cesari, et al., Mitochondrial dysfunction and sarcopenia of aging: From signaling pathways to clinical trials. International Journal of Biochemistry & Cell Biology, 2013. 45(10):2288-2301.

[42] Ekiz, T., M. Kara, A.M. Ata, et al., Rewinding sarcopenia: a narrative review on the renin-angiotensin system. Aging Clinical and Experimental Research, 2021. 33(9):2379-2392.

[43] Cabello-Verrugio, C., M.G. Morales, J.C. Rivera, et al., Renin-angiotensin system: an old player with novel functions in skeletal muscle. Med Res Rev, 2015. 35(3):437-463.

[44] Xing, E. and C. Wan, Prevalence of and factors associated with sarcopenia among elderly individuals with hypertension. Journal of International Medical Research, 2022. 50(7).

[45] Cruz-Jentoft, A.J. and A.A. Sayer, Sarcopenia. Lancet, 2019. 393(10191):2636-2646.

[46] Rosano, C., W.T. Longstreth, Jr., R. Boudreau, et al., High blood pressure accelerates gait slowing in well-functioning older adults over 18-years of follow-up. J Am Geriatr Soc, 2011. 59(3):390-397.

[47] Burton, L.A. and D. Sumukadas, Optimal management of sarcopenia. Clin Interv Aging, 2010. 5:217-228.

[48] Harber, M.P., A.R. Konopka, M.D. Douglass, et al., Aerobic exercise training improves whole muscle and single myofiber size and function in older women. Am J Physiol Regul Integr Comp Physiol, 2009. 297(5):R1452-1459.

[49] Maciorkowska, M., D. Musiałowska, and J. Małyszko, Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease. Adv Clin Exp Med, 2019. 28(11):1571-1575.

[50] Millar, P.J., C.L. McGowan, V.A. Cornelissen, et al., Evidence for the role of isometric exercise training in reducing blood pressure: potential mechanisms and future directions. Sports Med, 2014. 44(3):345-356.

[51] Liu, C.J. and N.K. Latham, Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev, 2009. 2009(3):Cd002759.

[52] Pedersen, A.N. and T. Cederholm, Health effects of protein intake in healthy elderly populations: a systematic literature review. Food Nutr Res, 2014. 58.

[53] Bauer, J., G. Biolo, T. Cederholm, et al., Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc, 2013. 14(8):542-559.

[54] Komar, B., L. Schwingshackl, and G. Hoffmann, Effects of leucine-rich protein supplements on anthropometric parameter and muscle strength in the elderly: a systematic review and meta-analysis. J Nutr Health Aging, 2015. 19(4):437-446.

[55] van Loon, L.J., Leucine as a pharmaconutrient in health and disease. Curr Opin Clin Nutr Metab Care, 2012. 15(1):71-77.

[56] Cermak, N.M., P.T. Res, L.C. de Groot, et al., Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. Am J Clin Nutr, 2012. 96(6):1454-1464.

[57] Kreider, R.B., D.S. Kalman, J. Antonio, et al., International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr, 2017. 14:18.

[58] Rooks, D. and R. Roubenoff, Development of Pharmacotherapies for the Treatment of Sarcopenia. J Frailty Aging, 2019. 8(3):120-130.

[59] Buford, T.W., T.M. Manini, F.C. Hsu, et al., Angiotensin-converting enzyme inhibitor use by older adults is associated with greater functional responses to exercise. J Am Geriatr Soc, 2012. 60(7):1244-1252.